S&P 500   3,859.59 (+0.46%)
DOW   31,701.24 (+0.65%)
QQQ   306.08 (-0.84%)
AAPL   119.32 (-1.73%)
MSFT   229.92 (-0.73%)
FB   262.90 (-0.52%)
GOOGL   2,078.00 (-0.91%)
TSLA   590.13 (-1.31%)
AMZN   3,016.38 (+0.53%)
NVDA   491.11 (-1.47%)
BABA   228.27 (-2.40%)
CGC   30.67 (-1.60%)
GE   14.14 (+3.97%)
MU   87.58 (-1.52%)
NIO   36.79 (-3.46%)
AMD   78.11 (-0.52%)
T   29.65 (+0.10%)
F   12.44 (+1.39%)
ACB   9.27 (-3.44%)
DIS   194.47 (+2.36%)
BA   228.00 (+2.14%)
NFLX   514.10 (-0.44%)
PFE   34.35 (-0.12%)
S&P 500   3,859.59 (+0.46%)
DOW   31,701.24 (+0.65%)
QQQ   306.08 (-0.84%)
AAPL   119.32 (-1.73%)
MSFT   229.92 (-0.73%)
FB   262.90 (-0.52%)
GOOGL   2,078.00 (-0.91%)
TSLA   590.13 (-1.31%)
AMZN   3,016.38 (+0.53%)
NVDA   491.11 (-1.47%)
BABA   228.27 (-2.40%)
CGC   30.67 (-1.60%)
GE   14.14 (+3.97%)
MU   87.58 (-1.52%)
NIO   36.79 (-3.46%)
AMD   78.11 (-0.52%)
T   29.65 (+0.10%)
F   12.44 (+1.39%)
ACB   9.27 (-3.44%)
DIS   194.47 (+2.36%)
BA   228.00 (+2.14%)
NFLX   514.10 (-0.44%)
PFE   34.35 (-0.12%)
S&P 500   3,859.59 (+0.46%)
DOW   31,701.24 (+0.65%)
QQQ   306.08 (-0.84%)
AAPL   119.32 (-1.73%)
MSFT   229.92 (-0.73%)
FB   262.90 (-0.52%)
GOOGL   2,078.00 (-0.91%)
TSLA   590.13 (-1.31%)
AMZN   3,016.38 (+0.53%)
NVDA   491.11 (-1.47%)
BABA   228.27 (-2.40%)
CGC   30.67 (-1.60%)
GE   14.14 (+3.97%)
MU   87.58 (-1.52%)
NIO   36.79 (-3.46%)
AMD   78.11 (-0.52%)
T   29.65 (+0.10%)
F   12.44 (+1.39%)
ACB   9.27 (-3.44%)
DIS   194.47 (+2.36%)
BA   228.00 (+2.14%)
NFLX   514.10 (-0.44%)
PFE   34.35 (-0.12%)
S&P 500   3,859.59 (+0.46%)
DOW   31,701.24 (+0.65%)
QQQ   306.08 (-0.84%)
AAPL   119.32 (-1.73%)
MSFT   229.92 (-0.73%)
FB   262.90 (-0.52%)
GOOGL   2,078.00 (-0.91%)
TSLA   590.13 (-1.31%)
AMZN   3,016.38 (+0.53%)
NVDA   491.11 (-1.47%)
BABA   228.27 (-2.40%)
CGC   30.67 (-1.60%)
GE   14.14 (+3.97%)
MU   87.58 (-1.52%)
NIO   36.79 (-3.46%)
AMD   78.11 (-0.52%)
T   29.65 (+0.10%)
F   12.44 (+1.39%)
ACB   9.27 (-3.44%)
DIS   194.47 (+2.36%)
BA   228.00 (+2.14%)
NFLX   514.10 (-0.44%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:EIGR

Eiger BioPharmaceuticals Stock Forecast, Price & News

$9.08
0.00 (0.00 %)
(As of 03/8/2021 09:40 AM ET)
Add
Compare
Today's Range
$9.00
Now: $9.08▼
$9.08
50-Day Range
$9.24
MA: $10.85▼
$12.30
52-Week Range
$4.55
Now: $9.08▼
$13.99
Volume467 shs
Average Volume298,363 shs
Market Capitalization$295.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Eiger BioPharmaceuticals logo

Headlines

Eiger Bio's Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient Setting
February 23, 2021 |  finance.yahoo.com
Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism
February 23, 2021 |  finance.yahoo.com
Eiger BioPharmaceuticals Announces US Commercial Availability Of Zokinvy For Progeria And Processing-Deficient Progeroid Laminopathies
January 26, 2021 |  benzinga.com
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
January 25, 2021 |  finance.yahoo.com
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
January 7, 2021 |  finance.yahoo.com
Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval
November 30, 2020 |  seekingalpha.com
FDA Approves Eiger Biopharma's Progeria Treatment: What Investors Should Know
November 23, 2020 |  msn.com
Eiger Bio (EIGR) rises 8% on sale of priority review voucher for $95M
November 23, 2020 |  seekingalpha.com
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million
November 23, 2020 |  finance.yahoo.com
First therapy for childhood aging disease wins FDA approval
November 21, 2020 |  bizjournals.com
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
November 20, 2020 |  finance.yahoo.com
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
November 20, 2020 |  msn.com
Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience™ 2020
November 17, 2020 |  finance.yahoo.com
Eiger Bio to Participate in November 2020 Investor Conferences
November 11, 2020 |  finance.yahoo.com
Eiger BioPharmaceuticals EPS beats by $0.07
November 7, 2020 |  seekingalpha.com
Eiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
November 5, 2020 |  finance.yahoo.com
Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience™ 2020
November 2, 2020 |  finance.yahoo.com
Will Eiger's Zokinvy Make History To Become First-ever Progeria Treatment?
November 2, 2020 |  nasdaq.com
Eiger BioPharmaceuticals Inc
October 31, 2020 |  bloomberg.com
Eiger BioPharmaceuticals: Peginterferon Lambda COVID-19 Data Very Positive
October 16, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
Previous Symbol
CUSIPN/A
CIK1305253
Webwww.eigerbio.com
Phone650-272-6138
Employees29
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.27
Current Ratio6.23
Quick Ratio6.23

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.31 per share
Price / Book3.93

Profitability

EPS (Most Recent Fiscal Year)($3.08)
Net Income$-70,250,000.00
Net MarginsN/A
Return on Equity-100.60%
Return on Assets-57.76%

Miscellaneous

Outstanding Shares32,532,000
Market Cap$295.39 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.61 out of 5 stars

Medical Sector

343rd out of 1,968 stocks

Biological Products, Except Diagnostic Industry

42nd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$9.08
0.00 (0.00 %)
(As of 03/8/2021 09:40 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Eiger BioPharmaceuticals?

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Eiger BioPharmaceuticals.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) released its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.09.
View Eiger BioPharmaceuticals' earnings history.

How has Eiger BioPharmaceuticals' stock been impacted by Coronavirus?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIGR shares have increased by 33.3% and is now trading at $9.08.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for EIGR?

2 brokerages have issued twelve-month target prices for Eiger BioPharmaceuticals' stock. Their forecasts range from $22.00 to $28.00. On average, they expect Eiger BioPharmaceuticals' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 175.3% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 57, Pay $862.03k)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Independent Director (Age 58, Pay $53.5k)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 40, Pay $461.98k)
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 50, Pay $417.8k)
  • Dr. Evan Loh, CEO of Paratek Pharmaceuticals & Director (Age 62, Pay $56k)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 60, Pay $55.5k)
  • Dr. Ingrid C. Choong, Sr. VP of Clinical Devel.
  • Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 54)
  • Mr. Rich Franco M.B.A., Sr. VP & Progeria Program Lead
  • Dr. Colin Hislop, Sr. VP of Clinical & Devel. Operations (Age 63)

Who are some of Eiger BioPharmaceuticals' key competitors?

Some companies that are related to Eiger BioPharmaceuticals include Coherus BioSciences (CHRS), Cortexyme (CRTX), Taysha Gene Therapies (TSHA), Adverum Biotechnologies (ADVM), Mesoblast (MESO), Rubius Therapeutics (RUBY), Inhibrx (INBX), Passage Bio (PASG), Black Diamond Therapeutics (BDTX), Aerie Pharmaceuticals (AERI), Aligos Therapeutics (ALGS), TCR2 Therapeutics (TCRR), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP) and CEL-SCI (CVM).
View all of EIGR's competitors.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.30%), Northern Trust Corp (1.33%), P.A.W. Capital Corp (1.23%), Laurion Capital Management LP (0.77%), Trellus Management Company LLC (0.63%) and JPMorgan Chase & Co. (0.63%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals.

Which major investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Caxton Corp, DRW Securities LLC, Barclays PLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Eiger BioPharmaceuticals or view top insider-selling stocks.

Which major investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was bought by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, BlackRock Inc., State of Wisconsin Investment Board, Squarepoint Ops LLC, P.A.W. Capital Corp, Dfpg Investments LLC, Engineers Gate Manager LP, and Nuveen Asset Management LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $9.08.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $295.39 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 29 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.